OncoMatch/Clinical Trials/NCT05319730
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Is NCT05319730 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for esophageal squamous cell carcinoma.
Treatment: Paclitaxel · Irinotecan · Pembrolizumab · MK-4830 · Lenvatinib · Sacituzumab tirumotecan · Antihistamine · H2 Receptor Antagonist · Acetaminophen (or equivalent) · Dexamethasone (or equivalent) · Steroid Mouthwash (dexamethasone or equivalent) · Supportive care measures — This is a Phase 1/2, multicenter, randomized, open-label umbrella platform study to evaluate the safety and efficacy of investigational agents with or without pembrolizumab and/or chemotherapy, for the treatment of participants with second line (2L) esophageal squamous cell carcinoma (ESCC) who have previously been exposed to PD-1/PD-L1 based treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Metastatic disease required
Prior therapy
Must have received: platinum-based chemotherapy
Must have received: anti-pd-1/pd-l1 therapy
Cannot have received: investigational agent
Lab requirements
Cardiac function
Clinically significant cardiovascular disease within 12 months from first dose of study intervention [excluded]
Clinically significant cardiovascular disease within 12 months from first dose of study intervention
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 4927) · Tucson, Arizona
- UCLA Hematology/Oncology - Santa Monica ( Site 4905) · Los Angeles, California
- Hematology-Oncology Associates of Central NY, P.C. ( Site 4925) · East Syracuse, New York
- Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 4907) · New York, New York
- UPMC Hillman Cancer Center-UPMC ( Site 4904) · Pittsburgh, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify